LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus

Sanofi

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Insulin glargine (LANTUS)

Study type: Observational

Funder types: Industry

Identifiers

NCT00423215

HOE901_5062

Details and patient eligibility

About

The objective of this protocol is to confirm the efficacy and safety profile of Lantus in every day medical practice, in type 2 diabetic patients, have been treated with any other insulin but who did not reach the target of A1c = 7%.

Enrollment: 1,007 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes mellitus,
• Having been treated with any other insulin, but who did not reach the target of A1c=7%.
• Ability and willingness to perform Self Monitoring Blood Glucose measurement

Exclusion criteria

• Will follow the prescribing information (Summary of Product Characteristics).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

1,007 participants in 1 patient group

Patients with Type II diabetes

Treatment:

Drug: Insulin glargine (LANTUS)